Education
About Us
Working with TipRanks
Follow Us
10x Genomics Inc (TXG)
NASDAQ:TXG
Total Valuation
10x Genomics has a market cap or net worth of $1.06B. The enterprise value is $1.44B.
Market Cap$1.06B
Enterprise Value$1.44B
Share Statistics
10x Genomics has 108.25M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding108.25M
Owened by Insiders2.14%
Owened by Instutions38.35%
Financial Efficiency
10x Genomics’s return on equity (ROE) is -0.26 and return on invested capital (ROIC) is -24.68%.
Return on Equity (ROE)-25.72%
Return on Assets (ROA)-19.88%
Return on Invested Capital (ROIC)-24.68%
Return on Capital Employed (ROCE)-24.29%
Revenue Per Employee$467,676.11
Profits Per Employee-$139,836.907
Employee Count1,306
Asset Turnover0.66
Inventory Turnover2.36
Valuation Ratios
The current PE Ratio of 10x Genomics is -9.47. 10x Genomics’s PEG ratio is 0.31.
PE Ratio-9.47
PS Ratio2.83
PB Ratio2.44
Price to Fair Value2.44
Price to FCF-301.92
Price to Operating Cash Flow259.56
PEG Ratio0.31
Income Statement
In the last 12 months, 10x Genomics had revenue of $610.78M and earned -$182.63M in profits. Earnings per share was -$1.53.
Revenue$610.78M
Gross Profit$419.81M
Operating Income-$192.46M
Pretax Income-$177.70M
Net Income-$182.63M
EBITDA-133.99M
Earnings Per Share (EPS)-1.53
Cash Flow
In the last 12 months, operating cash flow was $6.66M and capital expenditures -$13.39M, giving a free cash flow of -$6.73M billion.
Operating Cash Flow$6.66M
Free Cash Flow-$6.73M
Free Cash Flow per Share-$0.06
Dividends & Yields
10x Genomics pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-0.33%
Earnings Yield-10.56%
Stock Price Statistics
Beta1.70
52-Week Price Change-77.71%
50-Day Moving Average10.89
200-Day Moving Average16.16
Relative Strength Index (RSI)30.53
Average Volume (3m)3.30M
Important Dates
10x Genomics upcoming earnings date is Apr 30, 2025, After Close.
Last Earnings DateFeb 12, 2025
Next Earnings DateApr 30, 2025
Ex-Dividend Date―
Financial Position
10x Genomics as a current ratio of 4.97, with Debt / Equity ratio of 0.12
Current Ratio4.97
Quick Ratio4.26
Debt to Market Cap0.05
Net Debt to EBITDA1.95
Interest Coverage Ratio-48.64K
Taxes
In the past 12 months, 10x Genomics has paid $4.93M in taxes.
Income Tax$4.93M
Effective Tax Rate-2.77%
Enterprise Valuation
10x Genomics EV to EBITDA ratio is -10.96, with an EV/FCF ratio of -256.28.
EV to Sales2.40
EV to EBITDA-10.96
EV to Free Cash Flow-256.28
EV to Operating Cash Flow220.32
Balance Sheet
10x Genomics has $393.40M in cash and marketable securities with $82.61M in debt, giving a net cash position of -$310.79M billion.
Cash & Marketable Securities$393.40M
Total Debt$82.61M
Net Cash-$310.79M
Net Cash Per Share-$2.87
Tangible Book Value Per Share$5.73
Margins
Gross margin is 67.86%, with operating margin of -31.85%, and net profit margin of -29.90%.
Gross Margin67.86%
Operating Margin-31.85%
Pretax Margin-29.09%
Net Profit Margin-29.90%
EBITDA Margin-21.94%
EBIT Margin-29.09%
Analyst Forecast
The average price target for 10x Genomics is $16.09, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$16.09
Price Target Upside108.96%
Analyst ConsensusModerate Buy
Analyst Count12
Revenue Growth Forecast-1.28%
EPS Growth Forecast30.29%